Catalenas solutions for the opioid painkiller OxyContin are in high demand, as are anti-inflammatory drugs like Celebrex.The company recently raised $11.6 million in a Series B round led by Accel Partners and others.The firm has been aggressively building out its products, announcing an initial round of $2.5 billion in February and plans to raise another